n(1),n(11)-diethylnorspermine has been researched along with Melanoma in 14 studies
N(1),N(11)-diethylnorspermine: structure given in first source
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In MALME-3M human melanoma cells the polyamine analog N1,N12-bis(ethyl)spermine (BESPM) suppresses the key polyamine biosynthetic enzymes, ornithine and S-adenosylmethionine decarboxylase, and increases the polyamine catabolizing enzyme, spermidine/spermine N1-acetyl-transferase (SSAT) by more than 200-fold." | 7.68 | Polyamine and polyamine analog regulation of spermidine/spermine N1-acetyltransferase in MALME-3M human melanoma cells. ( Bergeron, RJ; Fogel-Petrovic, M; Porter, CW; Shappell, NW, 1993) |
| " Although the three sublines were 2- to 10-fold less sensitive than the parent line to classical MDR-type agents, they were found in dose-response studies to be significantly more sensitive to DENSPM than the parent line." | 5.29 | Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine. ( Bergeron, RJ; Ganis, B; Kramer, DL; Porter, CW; Rustum, Y; Wrzosek, C, 1994) |
| " Similar antitumor activity was obtained with 120 mg/kg once daily for 6 days and 40 mg/kg once daily for 6 days, indicating that against this tumor model, the dosing schedule can be relaxed up to sixfold without compromising antitumor activity." | 5.29 | Antitumor activity of N1,N11-bis(ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action. ( Bergeron, RJ; Bernacki, RJ; Miller, J; Porter, CW, 1993) |
| "We have previously shown that the clinically relevant polyamine analog N1,N11-diethylnorspermine (DENSPM) causes rapid apoptosis in human melanoma SK-MEL-28 cells via a series of events that include mitochondrial release of cytochrome c and activation of the caspase cascade." | 3.72 | Loss of inhibitor of apoptosis proteins as a determinant of polyamine analog-induced apoptosis in human melanoma cells. ( Chen, Y; Kramer, DL; Li, F; Porter, CW, 2003) |
| " We have found that treatment of MALME-3M human melanoma cells for 6 h with 10 micrograms/ml cycloheximide (CHX) increases ODC and SSAT mRNA 6-9-fold." | 3.69 | Differential post-transcriptional control of ornithine decarboxylase and spermidine-spermine N1-acetyltransferase by polyamines. ( Fogel-Petrovic, M; Miller, J; Porter, CW; Vujcic, S, 1996) |
| "In MALME-3M human melanoma cells the polyamine analog N1,N12-bis(ethyl)spermine (BESPM) suppresses the key polyamine biosynthetic enzymes, ornithine and S-adenosylmethionine decarboxylase, and increases the polyamine catabolizing enzyme, spermidine/spermine N1-acetyl-transferase (SSAT) by more than 200-fold." | 3.68 | Polyamine and polyamine analog regulation of spermidine/spermine N1-acetyltransferase in MALME-3M human melanoma cells. ( Bergeron, RJ; Fogel-Petrovic, M; Porter, CW; Shappell, NW, 1993) |
| "Fifteen patients with advanced solid tumors were entered into a phase I study of DENSPM given by a 1 h i." | 2.68 | Unusual central nervous system toxicity in a phase I study of N1N11 diethylnorspermine in patients with advanced malignancy. ( Berghorn, E; Creaven, PJ; Levine, E; Loewen, G; Meropol, NJ; Pendyala, L; Perez, R; Raghavan, D, 1997) |
| " Although the three sublines were 2- to 10-fold less sensitive than the parent line to classical MDR-type agents, they were found in dose-response studies to be significantly more sensitive to DENSPM than the parent line." | 1.29 | Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine. ( Bergeron, RJ; Ganis, B; Kramer, DL; Porter, CW; Rustum, Y; Wrzosek, C, 1994) |
| " Similar antitumor activity was obtained with 120 mg/kg once daily for 6 days and 40 mg/kg once daily for 6 days, indicating that against this tumor model, the dosing schedule can be relaxed up to sixfold without compromising antitumor activity." | 1.29 | Antitumor activity of N1,N11-bis(ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action. ( Bergeron, RJ; Bernacki, RJ; Miller, J; Porter, CW, 1993) |
| " In vitro studies indicated that the growth sensitivity of most tumor cell lines to DENSPM was similar, with characteristically flat dose-response curves and IC50s ranging between 0." | 1.29 | Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion. ( Atwood, A; Bergeron, RJ; Bernacki, RJ; Oberman, EJ; Porter, CW; Seweryniak, KE, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (71.43) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y | 3 |
| Alm, K | 1 |
| Vujcic, S | 5 |
| Kramer, DL | 7 |
| Kee, K | 1 |
| Diegelman, P | 5 |
| Porter, CW | 12 |
| Li, F | 1 |
| Minchin, RF | 1 |
| Knight, S | 1 |
| Arulpragasam, A | 1 |
| Fogel-Petrovic, M | 4 |
| Ganis, B | 1 |
| Rustum, Y | 1 |
| Wrzosek, C | 1 |
| Bergeron, RJ | 7 |
| Shappell, NW | 1 |
| Bernacki, RJ | 4 |
| Miller, J | 2 |
| Creaven, PJ | 1 |
| Perez, R | 1 |
| Pendyala, L | 1 |
| Meropol, NJ | 1 |
| Loewen, G | 1 |
| Levine, E | 1 |
| Berghorn, E | 1 |
| Raghavan, D | 1 |
| Cooley, JM | 1 |
| McManis, JS | 1 |
| Oberman, EJ | 1 |
| Seweryniak, KE | 1 |
| Atwood, A | 1 |
| White, C | 1 |
| Black, JD | 2 |
| Alderfer, J | 1 |
| Miller, JT | 1 |
1 review available for n(1),n(11)-diethylnorspermine and Melanoma
| Article | Year |
|---|---|
Polyamine analogue-mediated cell cycle responses in human melanoma cells involves the p53, p21, Rb regulatory pathway.
Topics: Acetyltransferases; Apoptosis; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme In | 1998 |
1 trial available for n(1),n(11)-diethylnorspermine and Melanoma
| Article | Year |
|---|---|
Unusual central nervous system toxicity in a phase I study of N1N11 diethylnorspermine in patients with advanced malignancy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Centr | 1997 |
12 other studies available for n(1),n(11)-diethylnorspermine and Melanoma
| Article | Year |
|---|---|
The role of mitogen-activated protein kinase activation in determining cellular outcomes in polyamine analogue-treated human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Enzyme Activation; Flavonoids; Humans; Kinetics; Melanoma; Mitogen | 2003 |
Loss of inhibitor of apoptosis proteins as a determinant of polyamine analog-induced apoptosis in human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Humans; Inhibitor of Apoptosis Proteins; Melanoma; Polyamines; Pro | 2003 |
Concentration-dependent effects of N1, N11-diethylnorspermine on melanoma cell proliferation.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neopla | 2006 |
Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine.
Topics: Adenosylmethionine Decarboxylase; Amidines; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 1994 |
Polyamine and polyamine analog regulation of spermidine/spermine N1-acetyltransferase in MALME-3M human melanoma cells.
Topics: Acetyltransferases; Adenosylmethionine Decarboxylase; Base Sequence; Blotting, Northern; Dactinomyci | 1993 |
Antitumor activity of N1,N11-bis(ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action.
Topics: Acetyltransferases; Adenosylmethionine Decarboxylase; Animals; Antineoplastic Agents; Dose-Response | 1993 |
Differential post-transcriptional control of ornithine decarboxylase and spermidine-spermine N1-acetyltransferase by polyamines.
Topics: Acetyltransferases; Blotting, Northern; Cell Line; Cycloheximide; Gene Expression Regulation, Enzymo | 1996 |
Effects of novel spermine analogues on cell cycle progression and apoptosis in MALME-3M human melanoma cells.
Topics: Acetyltransferases; Antineoplastic Agents; Apoptosis; Biogenic Polyamines; Cell Cycle; Cell Division | 1997 |
Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Drug Administratio | 1995 |
Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells.
Topics: Antineoplastic Agents; Blotting, Northern; Blotting, Western; Cell Division; Cyclin-Dependent Kinase | 1999 |
Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells.
Topics: Acetyltransferases; Antineoplastic Agents; Apoptosis; Biogenic Polyamines; Caspase 3; Caspases; Cyto | 2001 |
Antitumor activity of N,N'-bis(ethyl)spermine homologues against human MALME-3 melanoma xenografts.
Topics: Acetyltransferases; Animals; Cell Division; Dose-Response Relationship, Drug; Drug Administration Sc | 1992 |